Plasma and albumin‐free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients
- 1 August 2008
- journal article
- research article
- Published by Elsevier BV in Journal of Thrombosis and Haemostasis
- Vol. 6 (8), 1319-1326
- https://doi.org/10.1111/j.1538-7836.2008.03032.x
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Kinetic evaluation of four Factor VIII concentrates by model-independent methodsScandinavian Journal of Haematology, 2009
- Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe HemophiliaNew England Journal of Medicine, 2007
- Pharmacokinetics of recombinant factor VIII (Kogenate‐FS®) in children and causes of inter‐patient pharmacokinetic variabilityHaemophilia, 2006
- Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis StudyJournal of Thrombosis and Haemostasis, 2006
- Optimizing factor prophylaxis for the haemophilia population: where do we stand?Haemophilia, 2004
- Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin‐free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A1Haemophilia, 2004
- Clinical evaluation of B-domain deleted recombinant factor VIII in previously untreated patientsSeminars in Hematology, 2001
- Improved cost‐effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia AHaemophilia, 1997
- A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacsJournal of Internal Medicine, 1994
- Effect of height and weight on the in vivo recovery of transfused factor VIII C.Journal of Clinical Pathology, 1982